for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

IsoRay, Inc.

isr

Latest Trade

0.37USD

Change

0.00(+0.55%)

Volume

200,468

Today's Range

0.35

 - 

0.37

52 Week Range

0.27

 - 

0.61

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
0.37
Open
0.37
Volume
200,468
3M AVG Volume
2.77
Today's High
0.37
Today's Low
0.35
52 Week High
0.61
52 Week Low
0.27
Shares Out (MIL)
67.34
Market Cap (MIL)
24.59
Forward P/E
-4.30
Dividend (Yield %)
--

Latest Developments

More

IsoRay Files Prospectus Relating To Offering & Resale By Selling Stockholders Of Up To 5.8 Mln Shares

IsoRay Q3 Loss Per Share $0.02

Isoray Announces A New Training Collaboration With Texas Oncology

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About IsoRay, Inc.

IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.

Industry

Medical Equipment & Supplies

Contact Info

350 Hills St Ste 106

+1.509.3751202

https://isoray.com/

Executive Leadership

Michael W. McCormick

Chairman of the Board, Director

Lori A. Woods

Interim Chief Executive Officer, Director

Jennifer Streeter

Interim Chief Operating Officer, Vice President of Human Resources

Mark John Austin

Principal Accounting Officer, Co-Principal Financial Officer, Controller

Michael Krachon

Vice President, Director of Sales and Marketing

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.090

2017

-0.110

2018

-0.120

2019(E)

-0.085
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.52
Price To Book (MRQ)
2.86
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-78.02
Return on Equity (TTM)
-67.80

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up